State Drug Pricing Boards Pivot Toward Medicare-Based Upper Payment Limits as Early Models Stall

State prescription drug affordability boards are increasingly tying their price caps to Medicare negotiated prices rather than developing independent methodologies, with Colorado and Maryland leading this approach for products like Enbrel and Ozempic. However, no upper payment limit has actually taken effect yet, some states have dissolved their boards entirely, and aggressive bills in Virginia have faced repeated vetoes. The shift matters for Medicaid MCOs because these state pricing controls would directly affect pharmacy reimbursement rates and formulary strategies if they ultimately go into effect.

Pharmacy · Managed Care

This is outside commentary from Avalere, not part of Medicaid Monitor's independently scored news coverage.

More from Avalere